MD Anderson | Strategic Alliance Partners

Latest from MD Anderson


Nivolumab/Cabozantinib Continues to Showcase Deep, Durable Responses in Advanced RCC

October 11, 2021

Nivolumab plus cabozantinib continued to significantly improve overall response rate vs sunitinib in patients with previously untreated, advanced renal cell carcinoma, with meaningful response outcomes observed irrespective of dose modifications with cabozantinib and fewer responders in the doublet arm requiring subsequent treatment.

Immunotherapy, Second-Generation AR Antagonists Provide Expansive Utility Throughout Prostate Cancer

October 07, 2021

Sumit K. Subudhi, MD, PhD, discusses the treatment of patients with nonmetastatic castration-resistant prostate cancer, as well as those with metastatic castration-naïve, hormone-sensitive, and castration-resistant prostate cancer.

Later-Line Therapy in Metastatic CRC Calls for Safety Considerations in Refined Decision Making

September 30, 2021

Kanwal P.S. Raghav, MBBS, MD, discussed nuances to treatment selection in mCRC, the significance of the phase 2 ReDOS trial with regorafenib, and how the paradigms for mCRC, HCC, and gastroesophageal cancers have expanded from areas of unmet need to ones with more robust armamentariums.

Acalabrutinib Continues to Showcase Impressive Activity in Relapsed/Refractory MCL

September 21, 2021

Michael Wang, MD, discusses the impact of acalabrutinib in patients with mantle cell lymphoma, the implications of the phase 2 ACE-LY-004 trial, and the challenges faced with treating those who harbor TP53 mutations.

Liso-cel Plus Ibrutinib Demonstrates Tolerable Safety Profile in Relapsed/Refractory CLL/SLL

September 19, 2021

Lisocabtagene maraleucel in combination with ibrutinib was associated with manageable safety for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to updated data from the phase 1 TRANSCEND-CLL-004 trial.